Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q1
Impact factor
5.9
SJR
1.813
CiteScore
10.9
Categories
Hepatology
Areas
Medicine
Years of issue
2007-2025
journal names
Hepatology International
HEPATOL INT
Top-3 citing journals

Hepatology International
(1168 citations)

World Journal of Gastroenterology
(745 citations)

Liver International
(624 citations)
Top-3 organizations

Institute of Liver and Biliary Sciences
(107 publications)

Capital Medical University
(95 publications)

National Taiwan University Hospital
(74 publications)

Institute of Liver and Biliary Sciences
(55 publications)

Capital Medical University
(53 publications)
Most cited in 5 years
Found
Publications found: 1690
Q1

Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study
Smith H.T., Das S., Fettiplace J., von Maltzahn R., Troke P.J., McLaughlin M.M., Jones D.E., Kremer A.E.
Q1
Hepatology Communications
,
2025
,
citations by CoLab: 0
,

Open Access
Q1

Evidence-based criteria for identifying at-risk individuals requiring liver disease screening
Åberg F., Männistö V., Asteljoki J., Salomaa V., Jula A., Lundqvist A., Männistö S., Perola M., Luukkonen P.K.
Background:
Liver fibrosis screening is recommended in at-risk groups, but a clear definition of “at risk” for entry criteria is lacking. We analyzed different combinations of established risk factors to define specific screening entry criteria with a prespecified sensitivity requirement.
Methods:
Data regarding individuals aged 40–70 years from Finnish health-examination surveys (FINRISK 2002–2012 and Health 2000, n=15,057) and the UK Biobank (n=454,990) were linked with healthcare registries for liver cirrhosis-related events (LREs; liver-related hospitalizations, cancer, or death). The predictive performance of 1919 combinations of risk factors, including alcohol consumption, metabolic disturbances, abnormal liver function tests, and Chronic Liver Disease risk score, was assessed for 10-year LRE risk requiring a minimum 90% sensitivity. Validations were performed using liver stiffness measurement (LSM) >12 kPa in the NHANES 2017–2020 sample (n=3367).
Results:
Optimal entry criteria for predicting 10-year LRE risk with >90% sensitivity included any one of: hazardous alcohol use, severe obesity, metabolic syndrome, an AST-to-ALT ratio >0.8 with elevated ALT, and an intermediate-to-high Chronic Liver Disease risk score. The sensitivity and specificity for this strategy were 91% and 51% for LREs, respectively, in the Finnish cohort, and 91% and 41% for LSM >12 kPa in the US sample. In the US sample, applying these entry criteria followed by fibrosis-4 ≥1.3 for predicting LSM >12 kPa reduced the sensitivity to 45% (specificity: 85%), which was attributed to the suboptimal sensitivity of fibrosis-4.
Conclusions:
This study identifies an inexpensive risk factor-based strategy with >90% sensitivity for predicting LRE and LSM >12 kPa, which is practical and scalable for targeted liver fibrosis screening to improve population outcomes. However, a more sensitive first-line noninvasive fibrosis test is needed.
Q1

Advances in radiation therapy for HCC: Integration with liver-directed treatments
Yariv O., Newman N.B., Yarchoan M., Rabiee A., Wood B.J., Salem R., Hernandez J.M., Bang C.K., Yanagihara T.K., Escorcia F.E.
HCC is the fourth leading cause of cancer-related mortality with increasing incidence worldwide. Historically, treatment for early disease includes liver transplantation, surgical resection, and/or other local therapies, such as thermal ablation. As a result of technical advances and high-quality prospective data, the use of definitive external beam radiotherapy with ablative doses has emerged. Intermediate-stage disease has been generally addressed with arterially directed therapies (eg, chemoembolization or radioembolization) and external beam radiotherapy, while advanced stages have been addressed by systemic therapy or best supportive care. The role of each local/locoregional therapy has rapidly evolved in the context of novel pharmacotherapies, including immunotherapies and antiangiogenic agents. The combinations, indications, and timing of treatments vary widely among specialties and geographies. Here, we aim to synthesize the best quality evidence available regarding the efficacy and safety of different liver-directed modalities, with a focus on recent prospective clinical data of external beam radiotherapy within the context of other available liver-directed therapies across Barcelona Liver Classification (BCLC) stages.
Q1

Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo
Hong J.G., Trotman J., Carbajal Y., Dey P., Glass M., Sclar V., Alter I.L., Zhang P., Wang L., Chen L., Petitjean M., Bhattacharya D., Wang S., Friedman S.L., DeRossi C., et. al.
Background:
Fibrosis drives liver-related mortality in metabolic dysfunction–associated steatohepatitis (MASH), yet we have limited medical therapies to target MASH-fibrosis progression. Here we report that mannose, a simple sugar, attenuates MASH steatosis and fibrosis in 2 robust murine models and human liver slices.
Methods:
The well-validated fat-and-tumor MASH murine model for liver steatosis and fibrosis was employed. Mannose was supplied in the drinking water at the start (“Prevention” group) or at week 6 of the 12-week MASH regimen (“Therapy” group). The in vivo antifibrotic effects of mannose supplementation were tested in a second model of carbon tetrachloride (CCl4)-induced liver fibrosis. A quantitative and automated digital pathology approach was used to comprehensively assess steatosis and fibrosis phenotypes. Mannose was also tested in vitro in human and primary mouse hepatocytes conditioned with free fatty acids alone or with fructose, and human precision-cut liver slices from patients with end-stage MASH cirrhosis.
Results:
Oral mannose supplementation improved liver fibrosis in vivo in both fat-and-tumor MASH and CCl4 mouse models, as well as in human precision-cut liver slice MASH samples. Mannose also reduced liver steatosis in fat-and-tumor MASH mice, and in human and mouse hepatocytes in vitro. Ketohexokinase, the main enzyme in fructolysis, was decreased with mannose in whole mouse liver, cultured hepatocytes, and human precision-cut liver slices. Removal of fructose or overexpression of ketohexokinase each abrogated the antisteatotic effects of mannose.
Conclusions:
This study identifies mannose as a novel therapeutic candidate for MASH that mitigates steatosis by dampening hepatocyte ketohexokinase expression and exerts independent antifibrotic effects in 2 mouse models and human liver tissue slices.
Q1

Hyperbilirubinemia at hospitalization predicts nosocomial infection in decompensated cirrhosis: Data from ATTIRE trial
Fuller H., Tittanegro T.H., Maini A.A., China L., Rhodes F., Becares Salles N., Mukhopadhyay S., Moore B., O’Brien A.
Background:
To identify clinical characteristics and serological biomarkers that predicted subsequent nosocomial infection in ATTIRE trial patients.
Methods:
We identified 360 patients at hospitalization without infection and not prescribed antibiotics and compared clinical characteristics between those who subsequently developed a nosocomial infection and not. In a 68-patient subcohort, we compared plasma biomarkers of bacterial translocation, infection, and inflammation at hospitalization between those who developed a nosocomial infection and not. In a 56-patient subcohort, we investigated plasma lipidomic profiles in those who did and did not develop nosocomial infection using Lipotype Shotgun platform analysis and multivariate statistical techniques. To further investigate lipid pathways, we compared outcomes in patients taking statins or not at hospitalization.
Results:
Serum bilirubin >188 µmol/L at hospitalization predicted subsequent nosocomial infection in univariate and multivariate analyses, with 80% specificity. The most common nosocomial infections were respiratory tract (29%) and those developing infection had significantly greater 28 and 90-day mortality than those not (p=9.34E−05 and 0.014). Serological biomarkers of bacterial translocation, infection, and inflammation did not predict subsequent infection. Partial least squares discriminatory analyses identified cholesterol esters (CEs) (CE.18.1.2, CE.18.1.0, and CE.16.0.0) as important predictors of infection but provided only a small improvement in predictive ability over bilirubin alone. RNA-sequencing analyses suggest this is mediated by a downregulation of the cellular cholesterol esterification enzyme sterol O-acyltransferase 1. Statin use was not associated with nosocomial infection prevention.
Conclusions:
In ATTIRE, elevated serum bilirubin at hospitalization was the only clinical characteristic that predicted subsequent development of nosocomial infection. Considering the rising incidence of antimicrobial resistance, these data could be used to limit antibiotic prophylaxis or aid trial design for investigating use in high-risk patients.
Q1

EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation
Huang L., Zhong Q., Huang S., Yang K., Cai Y., Guo G.
Background:
The absence of representative Epstein-Barr virus–associated intrahepatic cholangiocarcinoma (EBVaICC) cell lines has limited our understanding of the molecular and immunological characteristics of this cancer subtype.
Methods:
We reviewed patients with metastatic cholangiocarcinoma at Sun Yat-sen University Cancer Center from January 2015 to August 2023. Among them, 22 patients with EBVaICC and 66 patients with non-EBVaICC who received anti-PD1 treatment were included. Additionally, 2 EBV-positive ICC cell lines, RBE-EBV and HuH28-EBV, were developed through cell-to-cell infection. Stable EBV infection and responsiveness to viral reactivation were confirmed. Transcriptomic and bioinformatics analyses were performed, and in vitro experiments examined the immune effects of EBV-positive ICC. Key immune-related genes and cytokines were validated by reverse transcription quantitative polymerase chain reaction and ELISA in cell lines and patient plasma samples.
Results:
In this study, we found that patients with EBVaICC showed enhanced immune responses and improved overall and progression-free survival compared to patients with non-EBVaICC. We first successfully established and validated 2 EBV-positive ICC cell lines (RBE-EBV and HuH28-EBV). These cell lines were confirmed for stable EBV infection and displayed responsiveness to viral reactivation, making them suitable for future studies. Transcriptomic analyses and in vitro studies revealed that EBV activated the cGAS-STING pathway, resulting in MHC-I upregulation and CXCL10 secretion in ICC cells, which collectively enhanced CD8+ T cell chemotaxis and cytotoxicity. Furthermore, ELISA analysis showed higher plasma levels of CXCL10 and IFN-γ in patients with EBVaICC, suggesting a potential role for EBV in enhancing immunotherapy sensitivity in this subtype.
Conclusions:
The established EBV-positive ICC cell lines revealed enhanced immunogenicity driven by cGAS-STING pathway activation, providing valuable models for future research and insights into the mechanisms of improved immunotherapy sensitivity in EBVaICC.
Q1

Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways
Li J., Kemper T., Broering R., Lin Y., Wang X., Lu M.
Background:
Autophagic and endosomal pathways coordinately contribute to HBV virions and subviral particles (SVPs) production. To date, limited evidence supports that HBV and exosomes have a common pathway for their biogenesis and secretion. The final steps of HBV production and release have not yet been well studied.
Methods:
We examined the production and release of HBV virions and SVPs by using GW4869 (N,N’-Bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-3,3’-pht hal amide dihydrochloride), a small molecule inhibiting ceramide-mediated inward membrane budding. Neutral sphingomyelinase, the target of GW4869, and RAB27A and –B, 2 small GTPases involved in exosome release control, were silenced using gene silencing to confirm the results obtained. Western blot, immunofluorescence staining, and confocal microscopy were applied.
Results:
GW4869 inhibited HBV virion release, causing their accumulation along with SVPs in hepatocytes. This triggered cellular endoplasmic reticulum stress, leading to protein kinase B-mechanistic target of rapamycin kinase signaling pathway inactivation. GW4869 treatment increased autophagosome formation and impaired autophagic degradation by blocking autophagosome-lysosome fusion. Consequently, HBsAg is increasingly localized to autophagosomes and late endosomes/multivesicular bodies. Silencing neutral sphingomyelinase yielded consistent results. Similarly, RAB27A silencing inhibited HBV virion and SVP secretion, causing their accumulation within hepatoma cells. Notably, GW4869 treatment, as well as RAB27A and -B silencing, increased the presence of LC3+CD63+HBsAg+ complexes.
Conclusions:
Our results demonstrate the involvement of the autophagosome-late endosome/multivesicular bodies-exosome axis in regulating HBV production and release, highlighting amphisomes as a potential platform for HBV release.
Q1

Unraveling enhanced liver regeneration in ALPPS: Integrating multi-omics profiling and in vivo CRISPR in mouse models
Du Y., Yang Y., Zhang Y., Zhang F., Wu J., Yin J.
Background:
Postoperative liver failure due to insufficient liver cell quantity and function remains a major cause of mortality following surgery. Hence, additional investigation and elucidation are required concerning suitable surgeries for promoting in vivo regeneration.
Methods:
We established the portal vein ligation (PVL) and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) mouse models to compare their in vivo regeneration capacity. Then, RNA-seq and microRNA-seq were conducted on the livers from both mouse models. Weighted gene co-expression network analysis algorithm was leveraged to identify crucial gene modules. ScRNA-seq analysis was used to understand the distinctions between Signature30high hepatocytes and Signature30low hepatocytes. Moreover, in vivo, validation was performed in fumarylacetoacetate hydrolase knockout mice with gene editing using the CRISPR-cas9 system. A dual luciferase report system was carried out to further identify the regulatory mechanisms.
Results:
RNA-seq analysis revealed that ALPPS could better promote cell proliferation compared to the sham and portal vein ligation models. Moreover, a Plk1-related 30-gene signature was identified to predict the cell state. ScRNA-seq analysis confirmed that signature30high hepatocytes had stronger proliferative ability than signature30low hepatocytes. Using microRNA-seq analysis, we identified 53 microRNAs that were time-dependently reduced after ALPPS. Finally, miR-30a-3p might be able to regulate the expression of Plk1, contributing to the liver regeneration of ALPPS.
Conclusions:
ALPPS could successfully promote liver regeneration by activating hepatocytes into a proliferative state. Moreover, a Plk1-related 30-gene signature was identified to predict the cell state of hepatocytes. miR-30a-3p might be able to regulate the expression of Plk1, contributing to the liver regeneration of ALPPS.
Q1

Pregnancy and liver-related outcomes after alcohol-associated hepatitis: A global multicenter study
Cooper K.M., Patel A.K., Kaluri S., Devuni D.
Background:
The incidence of alcohol-associated hepatitis (AH) is rising in women of reproductive age. While the adverse effects of alcohol on pregnancy are well documented, there is limited data on pregnancy in women with a history of AH.
Methods:
This study was completed by using the TriNetX Research Network. The primary objectives were to evaluate the incidence of pregnancy and related complications in pregnancies following an episode of AH (AH pregnancies) compared to pregnancies in healthy patients (control pregnancies). The secondary objective was to assess long-term liver-related complications and mortality in women with AH who experienced a pregnancy compared to no pregnancy. Propensity score matching was used for comparative analyses to balance cohorts by age, race, ethnicity, prior delivery, and obesity status.
Results:
The incidence of pregnancy was significantly lower in women with AH compared to controls (26 vs. 54 cases per 1000 person-years, p<0.001). AH pregnancies were associated with higher odds of spontaneous abortion (OR 2.0, 95% CI: 1.2 to 3.3, p
=0.011), pre-eclampsia (OR 1.9, 95% CI: 1.1 to 3.0, p
=0.002), peri-partum hemorrhage (OR 2.7, 95% CI: 1.3 to 5.6, p
=0.007) and perinatal psychiatric disorders (OR 3.2, 95% CI: 1.6 to 6.2, p
=0.001). The incidence of cirrhosis and hepatic decompensation were similar between women with AH who experienced a pregnancy compared to no pregnancy, but Kaplan Meier analysis revealed a significantly faster time to event in the no-pregnancy group.
Conclusions:
Pregnancies following AH diagnosis were associated with adverse pregnancy outcomes. Pregnancy after AH does not reduce the overall risk of developing advanced liver disease but may delay disease progression. These findings highlight the importance of tailored reproductive counseling and support for this population.
Q1

Second harmonic generation microscopy reveals the spatial orientation of glutamine-potentiated liver regeneration after hepatectomy
Yen C., Yen C., Tsai H., Yeh M.M., Hong T., Wang W., Liu I., Shan Y., Yen C.
Background:
Glutamine (Gln) is a critical amino acid for energy expenditure. It participates in extracellular matrix (ECM) formation and circulates in the hepatic parenchyma in a spatial-oriented manner. Posthepatectomy liver mass recovery poses a regenerative challenge. However, little is known about the role of Gln in liver regeneration, notably the spatial orientation in the remodeling process. This study aimed to elucidate Gln-potentiated liver regeneration and ECM remodeling after mass loss.
Methods:
We studied the regenerative process in hepatectomized mice supplemented with Gln. Second harmonic generation/two-photon excitation fluorescence microscopy, an artificial intelligence–assisted structure-based imaging, was used to demonstrate the spatial-oriented process in a hepatic acinus.
Results:
Gln promotes liver mass regrowth through the cell cycle, Gln metabolism, and adipogenesis pathways after hepatectomy. Ornithine transaminase, one of the upregulated enzymes, showed temporal, spatial, and functional correspondence with the regeneration process. Second harmonic generation/two-photon excitation fluorescence microscopy highlighted transient hepatic steatosis and ECM collagen synthesis, predominantly in the portal tract instead of the central vein area. Structural remodeling was also observed in the portal tract area.
Conclusions:
Gln promotes liver regeneration through cellular proliferation and metabolic reprogramming after hepatectomy. Using structure-based imaging, we found that Gln potentiated hepatic steatosis and ECM collagen deposition predominantly in the portal tract area. These results highlighted the spatial orientation and mechanistic implications of Gln in liver regeneration.
Q1

Gastroenterology and hepatology journals should increase women authorship representation: Room for improvement in trends from 2017 to 2024
Tsai C., Greenberg A., Flomenbaum D., Verzani Z., Garfunkel D., Brennan K., Nagamalla V., Mathew D.M., Tupchong S.A., Zhong L., Phillippi M.A., Fortune B.E., Abraham N., Tow C.Y.
Q1
Hepatology Communications
,
2025
,
citations by CoLab: 0
,

Open Access
Q1

Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes
Walker T., Nephew L.D.
Q1
Hepatology Communications
,
2025
,
citations by CoLab: 0
,

Open Access
Q1

Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in hepatocellular carcinoma
Dang M., Wang S., Peng F., Zhang R., Jiao H., Zhang H., Dong H., Zhang H., Xing J., Guo X., Liu Y.
Background:
Transarterial chemoembolization (TACE) is the primary treatment modality for advanced HCC, yet its efficacy assessment and prognosis prediction largely depend on imaging and serological markers that possess inherent limitations in terms of real-time capability, sensitivity, and specificity. Here, we explored whether multiple features of cell-free mitochondrial DNA (cf-mtDNA), including copy number, mutations, and fragmentomics, could be used to predict the response and prognosis of patients with HCC undergoing TACE treatment.
Methods:
A total of 60 plasma cell-free DNA samples were collected from 30 patients with HCC before and after the first TACE treatment and then subjected to capture-based mtDNA sequencing and whole-genome sequencing.
Results:
Comprehensive analyses revealed a clear association between cf-mtDNA multiple features and tumor characteristics. Based on cf-mtDNA multiple features, we also developed HCC death and progression risk prediction models. Kaplan-Meier curve analyses revealed that the high-death risk or high-progression–risk group had significantly shorter median overall survival (OS) and progression-free survival than the low-death risk or low-progression-risk group (all p<0.05). Moreover, the change in cf-mtDNA multiple features before and after TACE treatment exhibited an exceptional ability to predict the risk of death and progression in patients with HCC (log-rank test, all p<0.01; HRs: 0.36 and 0.33, respectively). Furthermore, we observed the consistency of change between the cf-mtDNA multiple features and copy number variant burden before and after TACE treatment in 40.00% (12/30) patients with HCC.
Conclusions:
Altogether, we developed a novel strategy based on profiling of cf-mtDNA multiple features for prognosis prediction and efficacy evaluation in patients with HCC undergoing TACE treatment.
Q1

Information overload, financial constraints, and psychological burdens are among the barriers faced by marginalized groups seeking curative treatments for HCC
Nephew L.D., Moore C., Garcia N., Parks L., McKay A., Strauss A.T., Wiehe S., Chalasani N., Hughes-Wegner A.T., Rawl S.M.
Background:
Patients with HCC face numerous barriers to curative therapies, particularly Black patients and those impacted by adverse social determinants of health (SDOH). This study aimed to identify patient-reported barriers and facilitators to curative therapies, to inform interventions that improve equitable access to care.
Methods:
We conducted 2 qualitative sessions with Black participants and participants experiencing adverse SDOH with HCC referred for liver transplant (LT) or resection. We also conducted one-on-one interviews with participants from sessions that underwent LT (n=2). Human-centered design methods, including journey mapping and group ideation, were used to identify challenges and solutions at various stages in the care pathway. Data were analyzed to identify key themes and to compare the experiences of Black patients with those experiencing adverse SDOH.
Results:
Both groups faced significant barriers, particularly related to information overload, communication gaps with health care providers, and the complexity of navigating the LT pathway. However, Black patients reported additional challenges related to the psychological burden of the diagnosis and distrust in the health care system, while those with adverse SDOH frequently cited financial instability, lack of social support, and challenges in coordinating care between multiple health systems. Despite these differences, common facilitators included compassionate health care teams and strong personal support networks. Both groups suggested solutions such as improvements in education timing and delivery, better communication pathways, and peer support groups to improve preparedness for treatment and recovery.
Conclusions:
While Black patients and those with adverse SDOH experience unique barriers, common threads—such as information gaps and desire for peer support suggest shared opportunities for interventions.
Q1

IL-8–NF-κB–ALDH1A1 loop promotes the progression of intrahepatic cholangiocarcinoma
Song Y., Li Y., Zhou J., Yu J., Hu Q., Yang F., Yin Z., Wang Y., Wang Y., Zhang X., Tao Y., Peng C., Liu S.
Background:
Intrahepatic cholangiocarcinoma (ICC) is a poor prognosis of malignant cancer with high lymph node metastasis and resistance to systemic therapies. Recent studies suggested that the involvement of IL-8 could promote ICC metastasis through epithelial–mesenchymal transition while the ICC-ALDH1A1high subtype is clarified by multi-omics study. The correlation between ALDH1A1 and IL-8 in ICC remains elusive. This study aims to further explore the roles and regulatory mechanisms of ALDH1A1 and IL-8 in ICC.
Methods:
We analyzed IL-8 and ALDH1A1 expression in ICC patients and cells. CXCR2 inhibitor (SB225002) was applied to inhibit the function of IL-8, and JSH-23 was applied to inhibit the NF-κB signaling pathway. We examined the effects of IL-8 inhibition on NF-κB, ALDH1A1 expression, and cell growth, migration, invasion, and stemness. Moreover, we examined the effects of ALDH1A1 on NF-κB, IL-8 expression, and cell growth, migration, invasion, and stemness. The effects of IL-8 and ALDH1A1 on tumor growth and NF-κB expression were validated using subcutaneous tumors in nude mice.
Results:
IL-8-derived tumor cells could promote ICC progression. The high expression of IL-8 in serum was associated with lymph node metastasis. IL-8 could upregulate ALDH1A1 expression by activating the NF-κB signaling pathway, promoting tumor progression. Upregulation of ALDH1A1 could activate NF-κB to promote IL-8 secretion, forming a positive feedback loop to promote tumor invasiveness and cell stemness in ICC.
Conclusions:
IL-8-derived tumor cells could upregulate ALDH1A1 expression by activating the NF-κB signaling pathway, promoting tumor progression. Upregulation of ALDH1A1 could activate NF-κB to promote IL-8 secretion, forming a positive feedback loop to promote tumor invasiveness and cell stemness in ICC.
Top-100
Citing journals
200
400
600
800
1000
1200
|
|
Hepatology International
1168 citations, 3.02%
|
|
World Journal of Gastroenterology
745 citations, 1.93%
|
|
Liver International
624 citations, 1.61%
|
|
Journal of Hepatology
563 citations, 1.46%
|
|
PLoS ONE
501 citations, 1.3%
|
|
Scientific Reports
473 citations, 1.22%
|
|
World Journal of Hepatology
429 citations, 1.11%
|
|
Hepatology
429 citations, 1.11%
|
|
International Journal of Molecular Sciences
426 citations, 1.1%
|
|
Journal of Gastroenterology and Hepatology (Australia)
420 citations, 1.09%
|
|
Journal of Viral Hepatitis
405 citations, 1.05%
|
|
Medicine (United States)
355 citations, 0.92%
|
|
Frontiers in Oncology
350 citations, 0.91%
|
|
Frontiers in Immunology
345 citations, 0.89%
|
|
Alimentary Pharmacology and Therapeutics
340 citations, 0.88%
|
|
Cancers
306 citations, 0.79%
|
|
Journal of Clinical and Experimental Hepatology
291 citations, 0.75%
|
|
Hepatology Research
291 citations, 0.75%
|
|
Journal of Clinical Medicine
247 citations, 0.64%
|
|
Frontiers in Medicine
246 citations, 0.64%
|
|
European Journal of Gastroenterology and Hepatology
232 citations, 0.6%
|
|
Digestive Diseases and Sciences
231 citations, 0.6%
|
|
Clinical Gastroenterology and Hepatology
201 citations, 0.52%
|
|
Clinical and molecular hepatology
200 citations, 0.52%
|
|
Viruses
189 citations, 0.49%
|
|
BMC Gastroenterology
183 citations, 0.47%
|
|
Clinics in Liver Disease
178 citations, 0.46%
|
|
Journal of Medical Virology
177 citations, 0.46%
|
|
Frontiers in Pharmacology
172 citations, 0.44%
|
|
Hepatology Communications
170 citations, 0.44%
|
|
Annals of Hepatology
166 citations, 0.43%
|
|
Expert Review of Gastroenterology and Hepatology
161 citations, 0.42%
|
|
JHEP Reports
157 citations, 0.41%
|
|
Current Hepatology Reports
153 citations, 0.4%
|
|
Journal of Hepatocellular Carcinoma
151 citations, 0.39%
|
|
Diagnostics
148 citations, 0.38%
|
|
Nutrients
141 citations, 0.36%
|
|
European Radiology
133 citations, 0.34%
|
|
Frontiers in Endocrinology
119 citations, 0.31%
|
|
Abdominal Radiology
117 citations, 0.3%
|
|
Antiviral Therapy
117 citations, 0.3%
|
|
World Journal of Clinical Cases
116 citations, 0.3%
|
|
BMC Infectious Diseases
111 citations, 0.29%
|
|
Journal of the Formosan Medical Association
110 citations, 0.28%
|
|
Biomedicines
110 citations, 0.28%
|
|
BMC Cancer
109 citations, 0.28%
|
|
Journal of Gastroenterology
108 citations, 0.28%
|
|
Journal of Clinical and Translational Hepatology
108 citations, 0.28%
|
|
Gastroenterology
106 citations, 0.27%
|
|
Digestive and Liver Disease
102 citations, 0.26%
|
|
Cells
102 citations, 0.26%
|
|
American Journal of Gastroenterology
97 citations, 0.25%
|
|
Liver Transplantation
97 citations, 0.25%
|
|
Hepatoma Research
97 citations, 0.25%
|
|
Gut
95 citations, 0.25%
|
|
Journal of Clinical Gastroenterology
93 citations, 0.24%
|
|
Oncotarget
92 citations, 0.24%
|
|
Clinics and Research in Hepatology and Gastroenterology
92 citations, 0.24%
|
|
Cureus
91 citations, 0.24%
|
|
Seminars in Liver Disease
89 citations, 0.23%
|
|
Biomedicine and Pharmacotherapy
86 citations, 0.22%
|
|
Liver Cancer
84 citations, 0.22%
|
|
Indian Journal of Gastroenterology
83 citations, 0.21%
|
|
Frontiers in Nutrition
80 citations, 0.21%
|
|
Frontiers in Microbiology
80 citations, 0.21%
|
|
Nature Reviews Gastroenterology and Hepatology
77 citations, 0.2%
|
|
Transplantation Proceedings
77 citations, 0.2%
|
|
Hepatobiliary and Pancreatic Diseases International
76 citations, 0.2%
|
|
Heliyon
76 citations, 0.2%
|
|
Reactions Weekly
75 citations, 0.19%
|
|
BioMed Research International
74 citations, 0.19%
|
|
Experimental and Therapeutic Medicine
71 citations, 0.18%
|
|
JGH Open
69 citations, 0.18%
|
|
Virology Journal
69 citations, 0.18%
|
|
Frontiers in Cellular and Infection Microbiology
68 citations, 0.18%
|
|
Antiviral Research
64 citations, 0.17%
|
|
International Immunopharmacology
62 citations, 0.16%
|
|
Clinical Liver Disease
61 citations, 0.16%
|
|
Journal of Infectious Diseases
61 citations, 0.16%
|
|
Hepatitis Monthly
59 citations, 0.15%
|
|
Journal of Pediatric Gastroenterology and Nutrition
55 citations, 0.14%
|
|
Egyptian Liver Journal
54 citations, 0.14%
|
|
European Journal of Radiology
53 citations, 0.14%
|
|
Frontiers in Genetics
52 citations, 0.13%
|
|
The Lancet Gastroenterology and Hepatology
52 citations, 0.13%
|
|
Radiology
52 citations, 0.13%
|
|
Transplantation
51 citations, 0.13%
|
|
Korean Journal of Radiology
50 citations, 0.13%
|
|
Cancer Medicine
50 citations, 0.13%
|
|
Oncology Letters
49 citations, 0.13%
|
|
Cochrane Database of Systematic Reviews
47 citations, 0.12%
|
|
Journal of Digestive Diseases
47 citations, 0.12%
|
|
Euroasian Journal of Hepato-Gastroenterology
47 citations, 0.12%
|
|
Journal of Personalized Medicine
46 citations, 0.12%
|
|
Gastroenterologia y Hepatologia
46 citations, 0.12%
|
|
Journal of Translational Medicine
46 citations, 0.12%
|
|
Chinese Medical Journal
44 citations, 0.11%
|
|
CardioVascular and Interventional Radiology
43 citations, 0.11%
|
|
Annals of Translational Medicine
43 citations, 0.11%
|
|
Canadian Journal of Gastroenterology and Hepatology
42 citations, 0.11%
|
|
Show all (70 more) | |
200
400
600
800
1000
1200
|
Citing publishers
1000
2000
3000
4000
5000
6000
7000
8000
|
|
Elsevier
7310 citations, 18.91%
|
|
Springer Nature
6878 citations, 17.79%
|
|
Wiley
5194 citations, 13.44%
|
|
MDPI
2727 citations, 7.05%
|
|
Frontiers Media S.A.
2014 citations, 5.21%
|
|
Ovid Technologies (Wolters Kluwer Health)
1644 citations, 4.25%
|
|
Baishideng Publishing Group
1590 citations, 4.11%
|
|
Taylor & Francis
1442 citations, 3.73%
|
|
Hindawi Limited
621 citations, 1.61%
|
|
SAGE
571 citations, 1.48%
|
|
Public Library of Science (PLoS)
539 citations, 1.39%
|
|
Oxford University Press
425 citations, 1.1%
|
|
Georg Thieme Verlag KG
344 citations, 0.89%
|
|
BMJ
325 citations, 0.84%
|
|
AME Publishing Company
306 citations, 0.79%
|
|
Spandidos Publications
298 citations, 0.77%
|
|
S. Karger AG
270 citations, 0.7%
|
|
The Korean Association for the Study of the Liver
223 citations, 0.58%
|
|
OAE Publishing Inc.
182 citations, 0.47%
|
|
Cold Spring Harbor Laboratory
160 citations, 0.41%
|
|
Ediciones Medicina y Cultura
159 citations, 0.41%
|
|
Impact Journals
138 citations, 0.36%
|
|
Xia & He Publishing
138 citations, 0.36%
|
|
American Chemical Society (ACS)
132 citations, 0.34%
|
|
Bentham Science Publishers Ltd.
121 citations, 0.31%
|
|
Mary Ann Liebert
117 citations, 0.3%
|
|
American Society for Microbiology
95 citations, 0.25%
|
|
Research Square Platform LLC
90 citations, 0.23%
|
|
80 citations, 0.21%
|
|
Royal Society of Chemistry (RSC)
76 citations, 0.2%
|
|
Radiological Society of North America (RSNA)
76 citations, 0.2%
|
|
Jaypee Brothers Medical Publishing
75 citations, 0.19%
|
|
Hans Publishers
69 citations, 0.18%
|
|
Walter de Gruyter
64 citations, 0.17%
|
|
IntechOpen
61 citations, 0.16%
|
|
American Physiological Society
54 citations, 0.14%
|
|
Medknow
54 citations, 0.14%
|
|
Japan Society of Hepatology
51 citations, 0.13%
|
|
Editorial Office of Gut and Liver
50 citations, 0.13%
|
|
Brieflands
50 citations, 0.13%
|
|
Japanese Society of Internal Medicine
47 citations, 0.12%
|
|
American Medical Association (AMA)
42 citations, 0.11%
|
|
Cambridge University Press
41 citations, 0.11%
|
|
XMLink
38 citations, 0.1%
|
|
37 citations, 0.1%
|
|
American Roentgen Ray Society
37 citations, 0.1%
|
|
Korean Society of Gastroenterology
36 citations, 0.09%
|
|
35 citations, 0.09%
|
|
American Association for Cancer Research (AACR)
34 citations, 0.09%
|
|
The Endocrine Society
32 citations, 0.08%
|
|
PeerJ
31 citations, 0.08%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
31 citations, 0.08%
|
|
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
27 citations, 0.07%
|
|
Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia/Brazilian Institute for Studies and Research in Gastroenterology
23 citations, 0.06%
|
|
IOS Press
22 citations, 0.06%
|
|
Portland Press
22 citations, 0.06%
|
|
Microbiology Society
21 citations, 0.05%
|
|
British Institute of Radiology
21 citations, 0.05%
|
|
JMIR Publications
21 citations, 0.05%
|
|
University of Toronto Press Inc. (UTPress)
21 citations, 0.05%
|
|
The Korean Society of Radiology
21 citations, 0.05%
|
|
IOP Publishing
19 citations, 0.05%
|
|
Media Sphere Publishing House
19 citations, 0.05%
|
|
18 citations, 0.05%
|
|
American Society for Pharmacology and Experimental Therapeutics
18 citations, 0.05%
|
|
American Diabetes Association
17 citations, 0.04%
|
|
Obsidiana Editores
17 citations, 0.04%
|
|
17 citations, 0.04%
|
|
F1000 Research
17 citations, 0.04%
|
|
American Society of Clinical Oncology (ASCO)
16 citations, 0.04%
|
|
American Society for Biochemistry and Molecular Biology
16 citations, 0.04%
|
|
SciELO
16 citations, 0.04%
|
|
Remedium, Ltd.
16 citations, 0.04%
|
|
The American Association of Immunologists
16 citations, 0.04%
|
|
The Korean Society of Radiology
16 citations, 0.04%
|
|
Moffitt Cancer Center
15 citations, 0.04%
|
|
Proceedings of the National Academy of Sciences (PNAS)
14 citations, 0.04%
|
|
American Association for the Advancement of Science (AAAS)
14 citations, 0.04%
|
|
Higher Education Press
14 citations, 0.04%
|
|
Eco-Vector LLC
14 citations, 0.04%
|
|
Edizioni Minerva Medica
14 citations, 0.04%
|
|
American Society for Nutrition
14 citations, 0.04%
|
|
Consilium Medicum
14 citations, 0.04%
|
|
Social Science Electronic Publishing
14 citations, 0.04%
|
|
Massachusetts Medical Society
13 citations, 0.03%
|
|
The Korean Association of Hepato-Biliary-Pancreatic Surgery
13 citations, 0.03%
|
|
American Society for Clinical Investigation
12 citations, 0.03%
|
|
12 citations, 0.03%
|
|
American College of Gastroenterology
12 citations, 0.03%
|
|
eLife Sciences Publications
12 citations, 0.03%
|
|
LLC Global Media Technology
12 citations, 0.03%
|
|
Federation of American Societies for Experimental Biology (FASEB)
11 citations, 0.03%
|
|
Korean Academy of Medical Sciences
11 citations, 0.03%
|
|
Annual Reviews
11 citations, 0.03%
|
|
Korean Association of Internal Medicine
11 citations, 0.03%
|
|
Pharmaceutical Society of Japan
10 citations, 0.03%
|
|
The Japanese Journal of Gastroenterological Surgery
10 citations, 0.03%
|
|
Asian Pacific Organization for Cancer Prevention
10 citations, 0.03%
|
|
10 citations, 0.03%
|
|
Russian Gastroenterolgocial Society
10 citations, 0.03%
|
|
Show all (70 more) | |
1000
2000
3000
4000
5000
6000
7000
8000
|
Publishing organizations
20
40
60
80
100
120
|
|
Institute of Liver and Biliary Sciences
107 publications, 6.1%
|
|
Capital Medical University
95 publications, 5.41%
|
|
National Taiwan University Hospital
74 publications, 4.22%
|
|
University of Hong Kong
63 publications, 3.59%
|
|
Peking University
57 publications, 3.25%
|
|
University of Tokyo
55 publications, 3.13%
|
|
People's Liberation Army General Hospital and Medical School (301 Hospital)
52 publications, 2.96%
|
|
Southern Medical University
50 publications, 2.85%
|
|
Fudan University
49 publications, 2.79%
|
|
Yonsei University
49 publications, 2.79%
|
|
Sun Yat-sen University
48 publications, 2.74%
|
|
National Taiwan University
46 publications, 2.62%
|
|
Chang Gung University
46 publications, 2.62%
|
|
Shanghai Jiao Tong University
44 publications, 2.51%
|
|
Huazhong University of Science and Technology
43 publications, 2.45%
|
|
Kaohsiung Medical University
43 publications, 2.45%
|
|
Chinese University of Hong Kong
43 publications, 2.45%
|
|
University of Sydney
42 publications, 2.39%
|
|
Chiba University
42 publications, 2.39%
|
|
Post graduate Institute of Medical Education and Research
41 publications, 2.34%
|
|
Zhejiang University
35 publications, 1.99%
|
|
Bangabandhu Sheikh Mujib Medical University
34 publications, 1.94%
|
|
Chongqing Medical University
32 publications, 1.82%
|
|
National Yang Ming Chiao Tung University
32 publications, 1.82%
|
|
Aga Khan University Hospital
30 publications, 1.71%
|
|
Taipei Veterans General Hospital
30 publications, 1.71%
|
|
Westmead Hospital
26 publications, 1.48%
|
|
Ankara University
25 publications, 1.42%
|
|
Stanford University
24 publications, 1.37%
|
|
Asan Medical Center
24 publications, 1.37%
|
|
University of Ulsan
24 publications, 1.37%
|
|
Nanjing University
23 publications, 1.31%
|
|
Second Military Medical University
23 publications, 1.31%
|
|
Wenzhou Medical University
22 publications, 1.25%
|
|
University of Malaya
21 publications, 1.2%
|
|
Chinese Academy of Medical Sciences & Peking Union Medical College
21 publications, 1.2%
|
|
Seoul National University
21 publications, 1.2%
|
|
Hallym University
21 publications, 1.2%
|
|
Sanjay Gandhi Postgraduate Institute of Medical Sciences
20 publications, 1.14%
|
|
National University of Singapore
20 publications, 1.14%
|
|
Chulalongkorn University
20 publications, 1.14%
|
|
All India Institute of Medical Sciences, Delhi
19 publications, 1.08%
|
|
Tzu Chi University
19 publications, 1.08%
|
|
Ogaki Municipal Hospital
19 publications, 1.08%
|
|
Nanjing Medical University
18 publications, 1.03%
|
|
Sungkyunkwan University
18 publications, 1.03%
|
|
University of Maryland, Baltimore
18 publications, 1.03%
|
|
Prince of Songkla University
17 publications, 0.97%
|
|
Catholic University of Korea
17 publications, 0.97%
|
|
Shandong University
17 publications, 0.97%
|
|
Mayo Clinic
17 publications, 0.97%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
16 publications, 0.91%
|
|
China Medical University (Taiwan)
16 publications, 0.91%
|
|
Royal Prince Alfred Hospital
16 publications, 0.91%
|
|
Zhengzhou University
16 publications, 0.91%
|
|
Paris Cité University
16 publications, 0.91%
|
|
University of Queensland
15 publications, 0.85%
|
|
Korea University
15 publications, 0.85%
|
|
Osaka Metropolitan University
15 publications, 0.85%
|
|
Kurume University
15 publications, 0.85%
|
|
Sichuan University
14 publications, 0.8%
|
|
Medical University of Vienna
14 publications, 0.8%
|
|
Guangxi Medical University
14 publications, 0.8%
|
|
Juntendo University
14 publications, 0.8%
|
|
Nanjing Drum Tower Hospital
13 publications, 0.74%
|
|
Hebei Medical University
13 publications, 0.74%
|
|
China Medical University (Liaoning)
13 publications, 0.74%
|
|
Auckland City Hospital
13 publications, 0.74%
|
|
Samsung Medical Center
13 publications, 0.74%
|
|
Lanzhou University
13 publications, 0.74%
|
|
University of Toronto
13 publications, 0.74%
|
|
University of Delhi
12 publications, 0.68%
|
|
Aga Khan University
12 publications, 0.68%
|
|
Tsinghua University
12 publications, 0.68%
|
|
National Cheng Kung University Hospital
12 publications, 0.68%
|
|
Harbin Medical University
12 publications, 0.68%
|
|
Mahidol University
12 publications, 0.68%
|
|
Severance Hospital
12 publications, 0.68%
|
|
Virginia Commonwealth University
12 publications, 0.68%
|
|
Christian Medical College, Vellore
11 publications, 0.63%
|
|
Jilin University
11 publications, 0.63%
|
|
Xi'an Jiaotong University
11 publications, 0.63%
|
|
Southeast University
11 publications, 0.63%
|
|
University College London
11 publications, 0.63%
|
|
Tianjin Medical University
11 publications, 0.63%
|
|
Monash University
11 publications, 0.63%
|
|
Inje University
11 publications, 0.63%
|
|
Icahn School of Medicine at Mount Sinai
11 publications, 0.63%
|
|
Okayama University
11 publications, 0.63%
|
|
Nihon University
11 publications, 0.63%
|
|
University of Strasbourg
10 publications, 0.57%
|
|
Guangzhou Medical University
10 publications, 0.57%
|
|
Anhui Medical University
10 publications, 0.57%
|
|
Yale University
10 publications, 0.57%
|
|
Shandong First Medical University
10 publications, 0.57%
|
|
University of Melbourne
10 publications, 0.57%
|
|
Siriraj Hospital
10 publications, 0.57%
|
|
Nagoya University
10 publications, 0.57%
|
|
University of Michigan
10 publications, 0.57%
|
|
Nippon Medical School
10 publications, 0.57%
|
|
Show all (70 more) | |
20
40
60
80
100
120
|
Publishing organizations in 5 years
10
20
30
40
50
60
|
|
Institute of Liver and Biliary Sciences
55 publications, 7.3%
|
|
Capital Medical University
53 publications, 7.04%
|
|
People's Liberation Army General Hospital and Medical School (301 Hospital)
45 publications, 5.98%
|
|
Peking University
39 publications, 5.18%
|
|
Fudan University
36 publications, 4.78%
|
|
Sun Yat-sen University
34 publications, 4.52%
|
|
National Taiwan University Hospital
33 publications, 4.38%
|
|
Southern Medical University
32 publications, 4.25%
|
|
Shanghai Jiao Tong University
31 publications, 4.12%
|
|
Chinese University of Hong Kong
29 publications, 3.85%
|
|
University of Hong Kong
26 publications, 3.45%
|
|
Zhejiang University
25 publications, 3.32%
|
|
National Taiwan University
23 publications, 3.05%
|
|
Huazhong University of Science and Technology
22 publications, 2.92%
|
|
Chang Gung University
22 publications, 2.92%
|
|
Kaohsiung Medical University
22 publications, 2.92%
|
|
University of Sydney
22 publications, 2.92%
|
|
Yonsei University
21 publications, 2.79%
|
|
Nanjing University
20 publications, 2.66%
|
|
Wenzhou Medical University
20 publications, 2.66%
|
|
Chinese Academy of Medical Sciences & Peking Union Medical College
19 publications, 2.52%
|
|
Post graduate Institute of Medical Education and Research
18 publications, 2.39%
|
|
Taipei Veterans General Hospital
18 publications, 2.39%
|
|
Westmead Hospital
17 publications, 2.26%
|
|
University of Tokyo
17 publications, 2.26%
|
|
Chongqing Medical University
16 publications, 2.12%
|
|
University of Ulsan
16 publications, 2.12%
|
|
Bangabandhu Sheikh Mujib Medical University
16 publications, 2.12%
|
|
Ogaki Municipal Hospital
15 publications, 1.99%
|
|
Second Military Medical University
14 publications, 1.86%
|
|
National Yang Ming Chiao Tung University
14 publications, 1.86%
|
|
Stanford University
14 publications, 1.86%
|
|
Asan Medical Center
14 publications, 1.86%
|
|
Shandong University
14 publications, 1.86%
|
|
Nanjing Medical University
13 publications, 1.73%
|
|
Nanjing Drum Tower Hospital
13 publications, 1.73%
|
|
Seoul National University
13 publications, 1.73%
|
|
Zhengzhou University
13 publications, 1.73%
|
|
Hallym University
13 publications, 1.73%
|
|
All India Institute of Medical Sciences, Delhi
12 publications, 1.59%
|
|
Medical University of Vienna
12 publications, 1.59%
|
|
National University of Singapore
12 publications, 1.59%
|
|
China Medical University (Taiwan)
12 publications, 1.59%
|
|
Chulalongkorn University
12 publications, 1.59%
|
|
Guangxi Medical University
12 publications, 1.59%
|
|
Ankara University
11 publications, 1.46%
|
|
Aga Khan University Hospital
11 publications, 1.46%
|
|
Tsinghua University
11 publications, 1.46%
|
|
Southeast University
11 publications, 1.46%
|
|
Sungkyunkwan University
11 publications, 1.46%
|
|
Lanzhou University
11 publications, 1.46%
|
|
University of Malaya
10 publications, 1.33%
|
|
Tianjin Medical University
10 publications, 1.33%
|
|
Shandong First Medical University
10 publications, 1.33%
|
|
Korea University
10 publications, 1.33%
|
|
Severance Hospital
10 publications, 1.33%
|
|
Catholic University of Korea
10 publications, 1.33%
|
|
Zhongda Hospital Southeast University
9 publications, 1.2%
|
|
Hebei Medical University
9 publications, 1.2%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
9 publications, 1.2%
|
|
Tzu Chi University
9 publications, 1.2%
|
|
Anhui Medical University
9 publications, 1.2%
|
|
Mahidol University
9 publications, 1.2%
|
|
Juntendo University
9 publications, 1.2%
|
|
Osaka Metropolitan University
9 publications, 1.2%
|
|
Nippon Medical School
9 publications, 1.2%
|
|
Christian Medical College, Vellore
8 publications, 1.06%
|
|
Guangzhou Medical University
8 publications, 1.06%
|
|
China Medical University (Liaoning)
8 publications, 1.06%
|
|
National Cheng Kung University Hospital
8 publications, 1.06%
|
|
Harbin Medical University
8 publications, 1.06%
|
|
Monash University
8 publications, 1.06%
|
|
Royal Prince Alfred Hospital
8 publications, 1.06%
|
|
Siriraj Hospital
8 publications, 1.06%
|
|
University of Science and Technology of China
8 publications, 1.06%
|
|
Mayo Clinic
8 publications, 1.06%
|
|
Sanjay Gandhi Postgraduate Institute of Medical Sciences
7 publications, 0.93%
|
|
Sichuan University
7 publications, 0.93%
|
|
Xi'an Jiaotong University
7 publications, 0.93%
|
|
National Sun Yat-sen University
7 publications, 0.93%
|
|
Peking Union Medical College Hospital
7 publications, 0.93%
|
|
Taipei Medical University
7 publications, 0.93%
|
|
University of Melbourne
7 publications, 0.93%
|
|
National Autonomous University of Mexico
7 publications, 0.93%
|
|
Ehime Prefectural Central Hospital
7 publications, 0.93%
|
|
Tongji University
6 publications, 0.8%
|
|
University College London
6 publications, 0.8%
|
|
Nantong University
6 publications, 0.8%
|
|
Southwest Medical University
6 publications, 0.8%
|
|
Fu Jen Catholic University
6 publications, 0.8%
|
|
University Hospital Southampton NHS Foundation Trust
6 publications, 0.8%
|
|
Samsung
6 publications, 0.8%
|
|
S. Orsola-Malpighi Polyclinic
6 publications, 0.8%
|
|
Samsung Medical Center
6 publications, 0.8%
|
|
Our Lady of Fatima University
6 publications, 0.8%
|
|
Hannover Medical School
6 publications, 0.8%
|
|
Virginia Commonwealth University
6 publications, 0.8%
|
|
Kyushu University Hospital
6 publications, 0.8%
|
|
University of Maryland, Baltimore
6 publications, 0.8%
|
|
Kurume University
6 publications, 0.8%
|
|
Show all (70 more) | |
10
20
30
40
50
60
|
Publishing countries
100
200
300
400
500
600
700
800
|
|
China
|
China, 701, 39.94%
China
701 publications, 39.94%
|
USA
|
USA, 273, 15.56%
USA
273 publications, 15.56%
|
Japan
|
Japan, 250, 14.25%
Japan
250 publications, 14.25%
|
India
|
India, 202, 11.51%
India
202 publications, 11.51%
|
Republic of Korea
|
Republic of Korea, 131, 7.46%
Republic of Korea
131 publications, 7.46%
|
Australia
|
Australia, 97, 5.53%
Australia
97 publications, 5.53%
|
United Kingdom
|
United Kingdom, 68, 3.87%
United Kingdom
68 publications, 3.87%
|
France
|
France, 58, 3.3%
France
58 publications, 3.3%
|
Singapore
|
Singapore, 58, 3.3%
Singapore
58 publications, 3.3%
|
Italy
|
Italy, 54, 3.08%
Italy
54 publications, 3.08%
|
Germany
|
Germany, 50, 2.85%
Germany
50 publications, 2.85%
|
Egypt
|
Egypt, 48, 2.74%
Egypt
48 publications, 2.74%
|
Pakistan
|
Pakistan, 48, 2.74%
Pakistan
48 publications, 2.74%
|
Thailand
|
Thailand, 48, 2.74%
Thailand
48 publications, 2.74%
|
Turkey
|
Turkey, 42, 2.39%
Turkey
42 publications, 2.39%
|
Canada
|
Canada, 40, 2.28%
Canada
40 publications, 2.28%
|
Indonesia
|
Indonesia, 39, 2.22%
Indonesia
39 publications, 2.22%
|
Malaysia
|
Malaysia, 37, 2.11%
Malaysia
37 publications, 2.11%
|
Bangladesh
|
Bangladesh, 34, 1.94%
Bangladesh
34 publications, 1.94%
|
Philippines
|
Philippines, 34, 1.94%
Philippines
34 publications, 1.94%
|
Spain
|
Spain, 33, 1.88%
Spain
33 publications, 1.88%
|
Netherlands
|
Netherlands, 24, 1.37%
Netherlands
24 publications, 1.37%
|
Brazil
|
Brazil, 20, 1.14%
Brazil
20 publications, 1.14%
|
Switzerland
|
Switzerland, 19, 1.08%
Switzerland
19 publications, 1.08%
|
Armenia
|
Armenia, 18, 1.03%
Armenia
18 publications, 1.03%
|
Austria
|
Austria, 17, 0.97%
Austria
17 publications, 0.97%
|
New Zealand
|
New Zealand, 17, 0.97%
New Zealand
17 publications, 0.97%
|
Saudi Arabia
|
Saudi Arabia, 17, 0.97%
Saudi Arabia
17 publications, 0.97%
|
Greece
|
Greece, 14, 0.8%
Greece
14 publications, 0.8%
|
Belgium
|
Belgium, 13, 0.74%
Belgium
13 publications, 0.74%
|
Denmark
|
Denmark, 12, 0.68%
Denmark
12 publications, 0.68%
|
Mexico
|
Mexico, 12, 0.68%
Mexico
12 publications, 0.68%
|
Nepal
|
Nepal, 12, 0.68%
Nepal
12 publications, 0.68%
|
Poland
|
Poland, 12, 0.68%
Poland
12 publications, 0.68%
|
Sri Lanka
|
Sri Lanka, 12, 0.68%
Sri Lanka
12 publications, 0.68%
|
Israel
|
Israel, 6, 0.34%
Israel
6 publications, 0.34%
|
Iran
|
Iran, 6, 0.34%
Iran
6 publications, 0.34%
|
Romania
|
Romania, 6, 0.34%
Romania
6 publications, 0.34%
|
Russia
|
Russia, 5, 0.28%
Russia
5 publications, 0.28%
|
Myanmar
|
Myanmar, 5, 0.28%
Myanmar
5 publications, 0.28%
|
Portugal
|
Portugal, 4, 0.23%
Portugal
4 publications, 0.23%
|
Argentina
|
Argentina, 4, 0.23%
Argentina
4 publications, 0.23%
|
Mongolia
|
Mongolia, 4, 0.23%
Mongolia
4 publications, 0.23%
|
Sweden
|
Sweden, 4, 0.23%
Sweden
4 publications, 0.23%
|
Cuba
|
Cuba, 3, 0.17%
Cuba
3 publications, 0.17%
|
Qatar
|
Qatar, 2, 0.11%
Qatar
2 publications, 0.11%
|
Norway
|
Norway, 2, 0.11%
Norway
2 publications, 0.11%
|
UAE
|
UAE, 2, 0.11%
UAE
2 publications, 0.11%
|
Slovakia
|
Slovakia, 2, 0.11%
Slovakia
2 publications, 0.11%
|
Tunisia
|
Tunisia, 2, 0.11%
Tunisia
2 publications, 0.11%
|
Finland
|
Finland, 2, 0.11%
Finland
2 publications, 0.11%
|
Czech Republic
|
Czech Republic, 2, 0.11%
Czech Republic
2 publications, 0.11%
|
Chile
|
Chile, 2, 0.11%
Chile
2 publications, 0.11%
|
Bolivia
|
Bolivia, 1, 0.06%
Bolivia
1 publication, 0.06%
|
Hungary
|
Hungary, 1, 0.06%
Hungary
1 publication, 0.06%
|
Vietnam
|
Vietnam, 1, 0.06%
Vietnam
1 publication, 0.06%
|
Ireland
|
Ireland, 1, 0.06%
Ireland
1 publication, 0.06%
|
Cambodia
|
Cambodia, 1, 0.06%
Cambodia
1 publication, 0.06%
|
Cyprus
|
Cyprus, 1, 0.06%
Cyprus
1 publication, 0.06%
|
Colombia
|
Colombia, 1, 0.06%
Colombia
1 publication, 0.06%
|
Kuwait
|
Kuwait, 1, 0.06%
Kuwait
1 publication, 0.06%
|
Lithuania
|
Lithuania, 1, 0.06%
Lithuania
1 publication, 0.06%
|
Morocco
|
Morocco, 1, 0.06%
Morocco
1 publication, 0.06%
|
Palestine
|
Palestine, 1, 0.06%
Palestine
1 publication, 0.06%
|
Peru
|
Peru, 1, 0.06%
Peru
1 publication, 0.06%
|
Slovenia
|
Slovenia, 1, 0.06%
Slovenia
1 publication, 0.06%
|
Sudan
|
Sudan, 1, 0.06%
Sudan
1 publication, 0.06%
|
Uganda
|
Uganda, 1, 0.06%
Uganda
1 publication, 0.06%
|
South Africa
|
South Africa, 1, 0.06%
South Africa
1 publication, 0.06%
|
Show all (39 more) | |
100
200
300
400
500
600
700
800
|
Publishing countries in 5 years
50
100
150
200
250
300
350
400
450
|
|
China
|
China, 401, 53.25%
China
401 publications, 53.25%
|
India
|
India, 90, 11.95%
India
90 publications, 11.95%
|
USA
|
USA, 87, 11.55%
USA
87 publications, 11.55%
|
Japan
|
Japan, 85, 11.29%
Japan
85 publications, 11.29%
|
Republic of Korea
|
Republic of Korea, 65, 8.63%
Republic of Korea
65 publications, 8.63%
|
Australia
|
Australia, 42, 5.58%
Australia
42 publications, 5.58%
|
United Kingdom
|
United Kingdom, 29, 3.85%
United Kingdom
29 publications, 3.85%
|
Singapore
|
Singapore, 26, 3.45%
Singapore
26 publications, 3.45%
|
Italy
|
Italy, 24, 3.19%
Italy
24 publications, 3.19%
|
Germany
|
Germany, 23, 3.05%
Germany
23 publications, 3.05%
|
Thailand
|
Thailand, 21, 2.79%
Thailand
21 publications, 2.79%
|
Malaysia
|
Malaysia, 20, 2.66%
Malaysia
20 publications, 2.66%
|
Pakistan
|
Pakistan, 19, 2.52%
Pakistan
19 publications, 2.52%
|
France
|
France, 18, 2.39%
France
18 publications, 2.39%
|
Indonesia
|
Indonesia, 18, 2.39%
Indonesia
18 publications, 2.39%
|
Canada
|
Canada, 18, 2.39%
Canada
18 publications, 2.39%
|
Turkey
|
Turkey, 18, 2.39%
Turkey
18 publications, 2.39%
|
Bangladesh
|
Bangladesh, 16, 2.12%
Bangladesh
16 publications, 2.12%
|
Philippines
|
Philippines, 16, 2.12%
Philippines
16 publications, 2.12%
|
Spain
|
Spain, 15, 1.99%
Spain
15 publications, 1.99%
|
Austria
|
Austria, 13, 1.73%
Austria
13 publications, 1.73%
|
Armenia
|
Armenia, 11, 1.46%
Armenia
11 publications, 1.46%
|
Egypt
|
Egypt, 10, 1.33%
Egypt
10 publications, 1.33%
|
Netherlands
|
Netherlands, 10, 1.33%
Netherlands
10 publications, 1.33%
|
Nepal
|
Nepal, 8, 1.06%
Nepal
8 publications, 1.06%
|
Brazil
|
Brazil, 7, 0.93%
Brazil
7 publications, 0.93%
|
Mexico
|
Mexico, 7, 0.93%
Mexico
7 publications, 0.93%
|
Switzerland
|
Switzerland, 7, 0.93%
Switzerland
7 publications, 0.93%
|
Greece
|
Greece, 6, 0.8%
Greece
6 publications, 0.8%
|
Denmark
|
Denmark, 6, 0.8%
Denmark
6 publications, 0.8%
|
Saudi Arabia
|
Saudi Arabia, 6, 0.8%
Saudi Arabia
6 publications, 0.8%
|
Sri Lanka
|
Sri Lanka, 5, 0.66%
Sri Lanka
5 publications, 0.66%
|
Romania
|
Romania, 4, 0.53%
Romania
4 publications, 0.53%
|
Belgium
|
Belgium, 3, 0.4%
Belgium
3 publications, 0.4%
|
Iran
|
Iran, 3, 0.4%
Iran
3 publications, 0.4%
|
Mongolia
|
Mongolia, 3, 0.4%
Mongolia
3 publications, 0.4%
|
Myanmar
|
Myanmar, 3, 0.4%
Myanmar
3 publications, 0.4%
|
Sweden
|
Sweden, 3, 0.4%
Sweden
3 publications, 0.4%
|
Argentina
|
Argentina, 2, 0.27%
Argentina
2 publications, 0.27%
|
New Zealand
|
New Zealand, 2, 0.27%
New Zealand
2 publications, 0.27%
|
Poland
|
Poland, 2, 0.27%
Poland
2 publications, 0.27%
|
Russia
|
Russia, 1, 0.13%
Russia
1 publication, 0.13%
|
Portugal
|
Portugal, 1, 0.13%
Portugal
1 publication, 0.13%
|
Bolivia
|
Bolivia, 1, 0.13%
Bolivia
1 publication, 0.13%
|
Israel
|
Israel, 1, 0.13%
Israel
1 publication, 0.13%
|
Ireland
|
Ireland, 1, 0.13%
Ireland
1 publication, 0.13%
|
Cambodia
|
Cambodia, 1, 0.13%
Cambodia
1 publication, 0.13%
|
Kuwait
|
Kuwait, 1, 0.13%
Kuwait
1 publication, 0.13%
|
UAE
|
UAE, 1, 0.13%
UAE
1 publication, 0.13%
|
Palestine
|
Palestine, 1, 0.13%
Palestine
1 publication, 0.13%
|
Peru
|
Peru, 1, 0.13%
Peru
1 publication, 0.13%
|
Slovakia
|
Slovakia, 1, 0.13%
Slovakia
1 publication, 0.13%
|
Sudan
|
Sudan, 1, 0.13%
Sudan
1 publication, 0.13%
|
Uganda
|
Uganda, 1, 0.13%
Uganda
1 publication, 0.13%
|
Finland
|
Finland, 1, 0.13%
Finland
1 publication, 0.13%
|
Czech Republic
|
Czech Republic, 1, 0.13%
Czech Republic
1 publication, 0.13%
|
South Africa
|
South Africa, 1, 0.13%
South Africa
1 publication, 0.13%
|
Show all (27 more) | |
50
100
150
200
250
300
350
400
450
|
3 profile journal articles
George Jacob
52 publications,
1 037 citations
h-index: 11
1 profile journal article
De Velasco Marco

Kindai University
99 publications,
2 839 citations
h-index: 31